FDA Guidance Clarifies Facility Requirements
US Agency Details Facilities That ANDAs And BLAs Should Note
The US FDA has made a renewed effort to clarify the types of manufacturing facilities that need to be listed on the Form FDA 356h and Module 3 of the CTD in submissions. Often reviewers find this information missing, which can result in a refuse to file action.
You may also be interested in...
Industry complained draft guidance would have made manufacturing establishment information harder to report, not easier.
Agency officials don't care if DMF holder doesn't give access to its entire facility list; FDA says industry is responsible for listing all facilities that could be used as part of ANDA.
Combining manufacturing establishment information (MEI) in one electronic form as part of new drug submissions could make review more straightforward and efficient, US agency says.